Neuroscience 2023

Sino Biological, Inc. is a global leader in manufacturing affordable, high-quality reagents, including recombinant proteins, antibodies and cDNA clones-all in-house. We provide a one-stop shop for researchers and pharmaceutical companies around the world, helping our customers ... obtain the best reagents in the needed amounts to accelerate the pace of discovery and improve human health.

BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Guided by our award-winning entrepreneurial leadership team, we ... have secured loyal customers and trusted partners at the world's premier research institutions, biotechnology and pharmaceutical companies. Our scientists collaboratively develop cutting-edge research and diagnostic products, establishing BioLegend as a global leader in immunology, cancer research, neuroscience, cell biology, proteogenomics, stem cells, and other emerging sectors. Recognized as one of the fastest growing life science companies, BioLegend transforms the boundaries of innovation for basic science and medical researchers world-wide. To learn more, visit www.biolegend.com

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications ... NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

Atlas Antibodies is a Swedish biotechnology company driving leading research worldwide through providing affinity-purified monoclonal and polyclonal antibodies, and control antigens. Our product portfolio extensively covers human proteins in cells, tissues, and organs. With our ... roots in the Human Protein Atlas project, an integration of antibody-based imaging, proteomics, and transcriptomics, our antibodies are selective and specific for their target proteins through our extensive validation process, ensuring reproducible results. We support you in your research. Our scientific support content and newsletter provide you with timely information about new product releases, research highlights, posters, infographics, and much more. In addition, our website contains informative whitepapers, protocols, guides, roundups of recent research papers, and blog posts. We're growing fast, having acquired two companies in 2021. UK-based Histocyte Laboratories produces high quality, reproducible cell line controls for same-slide use in histopathology available in multiple formats to suit your specific workflow and requirements. evitria is a world leading, global recombinant antibody expression service provider located in Zurich, Switzerland.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics.

For over 30 years, Miltenyi Biotec has been a leader in the development of products that empower the advancement of biomedical research and enable cell and gene therapy. We provide innovative tools to help with your sample preparation, cell isolation, cell culture, and cell ... analysis needs. Our solutions are designed to support everything from basic research to translational research and clinical application for immunology, stem cell biology, neuroscience, and cancer.

OriGene Technologies was founded as a research tool company focused on the creation of the large commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based ... tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 40,000 human full-length TrueClone cDNA collection and over 35,000 human TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the broad offering of full length human proteins, such as "MVPro" proteins, expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB™ project to develop mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein. OriGene also began the TrueRAB™ project to develop single B cell cloning technology for the generation of recombinant rabbit monoclonal antibodies with high affinity and against targets with low immunogenicity in mouse system. In addition, OriGene offers different gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be "Your Gene Company", in supplying everything a researcher needs for gene based research. For more information, please visit us at www.origene.com